FIELD: biotechnologies.
SUBSTANCE: poxvirus includes defective gene I4L and/or F4L and target nucleic acid containing suicide gene. Besides, a composition containing such a poxvirus, its use for obtaining medical preparation and a treatment method of proliferative disease or disease with increased activity of osteoclasts with its application are described. The proposed group of inventions can be used in medicine.
EFFECT: poxvirus of variolovaccine has oncolytic activity.
34 cl, 18 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| POXVIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2508401C2 |
| POX VIRAL ONCOLYTIC VECTORS | 2008 |
|
RU2557312C2 |
| M2-DEFECTIVE POXVIRUS | 2019 |
|
RU2819245C2 |
| COMBINATION OF ONCOLYTIC VIRUS WITH MODULATORS OF IMMUNOLOGICAL CONTROL POINTS | 2015 |
|
RU2705780C2 |
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
| PERSONALIZED VACCINE | 2018 |
|
RU2779987C2 |
| RECOMBINANT VARIOLOVACCINE VIRUS STRAIN VV-NS1-dGF PRODUCING NS1 PARVOVIRUS H-1 PROTEIN AND HAVING ONCOLYTIC ACTIVITY ON HUMAN GLIOBLASTOMA | 2018 |
|
RU2692628C1 |
| COMBINATION THERAPY FOR CANCER TREATMENT USING RECOMBINANT MVA AND ANTIBODIES INTRODUCED INTRAVENOUSLY | 2018 |
|
RU2795103C2 |
| VIRAL VACCINES | 2017 |
|
RU2778312C2 |
